These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21450529)

  • 21. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
    Fox EJ; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
    Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
    Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
    J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
    Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
    J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)].
    Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):93-9. PubMed ID: 23675607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glatiramer acetate.
    Comi G; Moiola L
    Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
    Cutter GR; Knappertz V; Sasson N; Ladkani D
    BMC Neurol; 2016 Sep; 16():176. PubMed ID: 27639853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
    Expert Rev Clin Immunol; 2010 Jul; 6(4):509. PubMed ID: 20594121
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral laquinimod for treatment of relapsing-remitting multiple sclerosis.
    Weiner HL
    Lancet Neurol; 2008 Aug; 7(8):672-3. PubMed ID: 18635014
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].
    Brassat D
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1014-28. PubMed ID: 11787332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
    Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
    Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.
    Rouhi F; Mohammadpour Z; Noureini SK; Abbastabar H; Harirchian MH; Bitarafan S
    Eur J Clin Pharmacol; 2020 May; 76(5):611-622. PubMed ID: 32020320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
    Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
    D'Amico E; Messina S; Caserta C; Patti F
    Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.